Luye Pharma makes strategic cross-border acquisition

0
1576
LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link

Luye Pharma Hong Kong and AstraZeneca have entered into a US$546 million agreement on the acquisition of AstraZeneca’s antidepressant medicines – a complex transaction that required well co-ordinated cross-border legal efforts.

AstraZeneca agreed to transfer and license to Luye Pharma the assets and rights related to Seroquel and Seroquel XR – atypical anti-psychotic medicines with antidepressant properties – in 51 countries and regions including the UK, China, Brazil, Australia, Saudi Arabia, Mexico, South Korea, Thailand, Argentina, Malaysia and South Africa.

Huang JianwenPartnerKing & Wood Mallesons
Huang Jianwen
Partner
King & Wood Mallesons

“Cross-border M&A requires lead counsel not only to have a wealth of experience and professional capability, but also to co-ordinate with counsel from different jurisdictions and practice areas,” Huang Jianwen, a partner at King & Wood Mallesons in Beijing, told China Business Law Journal.

You must be a subscribersubscribersubscribersubscriber to read this content, please subscribesubscribesubscribesubscribe today.

For group subscribers, please click here to access.
Interested in group subscription? Please contact us.

你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章,欢迎成为我们的订阅会员成为我们的订阅会员

已有集团订阅,可点击此处继续浏览。
如对集团订阅感兴趣,请联络我们

LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link